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Methylphenidate Has Differential Effects on Blood
Oxygenation Level-Dependent Signal Related to Cognitive
Subprocesses of Reversal Learning
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Complete understanding of the neural mechanisms by which stimulants such as methylphenidate ameliorate attention deficit hyperac-
tivity disorder is lacking. Theories of catecholamine function predict that the neural effects of stimulant drugs will vary according to task
requirements. We used event-related, pharmacological functional magnetic resonance imaging to investigate the effects of 60 mg of
methylphenidate, alone and in combination with 400mg of sulpiride, on blood oxygenation level-dependent (BOLD) signal in a group of
20healthyparticipants duringprobabilistic reversal learning, in a placebo-controlleddesign. In awhole-brain analysis,methylphenidate
attenuatedBOLDsignal in theventral striatumduring response switchingafternegative feedbackbutmodulatedactivity in theprefrontal
cortex when subjectsmaintained their current response set. The results show that the precise neural site ofmodulation bymethylpheni-
date depends on the nature of the cognitive subprocess recruited.
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Introduction
Methylphenidate, a stimulant that blocks the transporters of the
catecholamines dopamine and noradrenaline (Seeman and Ma-
dras, 1998), is used to treat attention deficit hyperactivity disor-
der (ADHD), a disorder characterized by inattention, impulsiv-
ity, and hyperactivity (Barkley, 1997; Nigg, 2001).
Methylphenidate has been shown to modulate neural activity in
the striatum during response inhibition (Vaidya et al., 1998) and
divided attention (Shafritz et al., 2004) but parietofrontal regions
during working memory (Mehta et al., 2000; Szobot et al., 2003).
Thus, the precise neural site of modulation by methylphenidate
appears to dependon the cognitive requirements of the task being
performed (Cools and Robbins, 2004). Specifically, according to
recent theorizing and empirical work, dopamine has been pro-
posed to facilitate the flexible updating of task representations by
acting at the level of the striatum while promoting the mainte-
nance of stable task representations by acting at the level of the
prefrontal cortex (PFC) (Frank et al., 2001; Bilder et al., 2004;
Seamans and Yang, 2004; Cools et al., 2007a).
In the present study, we tested these hypotheses by examining
the effects of the catecholamine enhancer methylphenidate on
blood oxygenation level-dependent (BOLD) signal during dis-
tinct subcomponent processes of probabilistic reversal learning.
We used a well established two-choice visual discrimination task
(Cools et al., 2002), in which subjects receive immediate feedback
after their choice of one of two abstract patterns presented in the
left and right visual fields. On each trial, participantsmust choose
the correct stimulus from two options and, when the stimulus-
outcome contingencies reverse, select the previously incorrect
stimulus instead. Presentation of occasional spurious negative
feedback also allowed the examination of neural activity associ-
atedwith the receipt ofmisleading negative feedback that was not
followed by behavioral switching. The hypothesis that striatal
dopamine is important in the flexible updating of task represen-
tations leads to the prediction that methylphenidate modulates
BOLD signal in the striatum during response switching, i.e., the
requirement to adapt responding to the new stimulus-outcome
rule. In contrast, the hypothesis that prefrontal dopamine is im-
portant in themaintenance of stable task representations leads to
the prediction that methylphenidate modulates BOLD signal in
the prefrontal cortex during the receipt of misleading negative
feedback because of the requirement to maintain the current
response set in the face of distraction.
This investigationwas performed as part of a larger design that
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also examined the possible opposing effects of sulpiride, a dopa-
mine D2 receptor antagonist, to test whether the effects of meth-
ylphenidate are mediated specifically by dopamine D2 receptor
signaling. Healthy participants were scanned while performing
the reversal learning task after receiving either placebo, 60 mg of
methylphenidate, 400 mg of sulpiride, or 60 mg of methylpheni-
date and 400 mg of sulpiride together. A possible confound in
pharmacological functional magnetic resonance imaging (fMRI)
studies arises from the fact that neurotransmitters such as dopa-
mine exert direct effects on regional vasoactivity (Krimer et al.,
1998). To account for this possibility, participants also per-
formed a passive-viewing checkerboard task. If any modulation
of BOLD signal in the reversal learning task is attributable to such
neurovascular effects, then similar modulations in the checker-
board task would be expected.
Materials andMethods
Participants. Twenty healthy volunteers (mean age, 22.2 years; range,
19–33 years; 14 male and 6 female; all right-handed) completed four
testing sessions each. Data from three participants were excluded from
the final analysis attributable to problems with fMRI data acquisition in
at least one session. Mean NART (National Adult Reading Test) value
was 121, with a range of 116–126. Participants were recruited among
students and staff of University of Cambridge and Addenbrooke’s Hos-
pital. All participants entered the study after screening by a research
psychiatrist (U.M.) and had no major psychiatric, neurological, or med-
ical illness, including alcohol and drug abuse. They were asked to abstain
from alcohol for 12 h, as well as from caffeine and nicotine for 3 h, before
the testing sessions. A light breakfast or snackwas allowed before, but not
during, the experimental session. All participants were questioned about
compliance with alcohol and caffeine restrictions before inclusion into
the study. All participants gave written informed consent before testing
and received monetary compensation of £200. The protocol was ap-
proved by the Local ResearchEthicsCommitteeCambridge (LRECnum-
ber 03/266) and formally exempted from clinical trial regulations by
Medicines and Healthcare Products Regulatory Agency.
Pharmacological design and procedures. All 20 participants completed
the protocol and were tested in four pharmacological conditions using a
counterbalanced, placebo-controlled, double-blind design. The four
conditions were placebo, methylphenidate, sulpiride, and methylpheni-
date and sulpiride combined. The minimum time between testing ses-
sions was 3 d. Single oral doses of 60 mg of methylphenidate (Ritalin;
Novartis), 400mg of sulpiride (Dolmatil; Sanofi-Synthelabo), or placebo
(lactose with microcrystalline cellulose) contained in identical opaque
gelatin capsules were administered 2 h
(sulpiride) or 1.5 h (methylphenidate) before
fMRI scanning. Because of the different phar-
macokinetics of the two drugs, a double dummy
procedure was used, whereby in every testing
session participants were given two capsules 2 h
before testing, containing either sulpiride or
placebo, and then an additional three capsules
1.5 h before testing, containing either methyl-
phenidate or placebo. Dose selection was based
on previous, similar studies showing behavioral
effects at similar (and lower) doses using the
same drugs in healthy volunteers (Mehta et al.,
1999, 2000;Volkow et al., 2002). The timing of
fMRI testing was performed at approximately
the time of maximal plasma levels of both drugs
based on pharmacokinetic data (Sugnaux et al.,
1983; Wagstaff et al., 1994; Kimko et al., 1999).
Between dosing and scanning, all volunteers
were asked to spend the waiting time with low
arousing activities (reading, watching television,
etc.) in a day room and were monitored by re-
search nurses.
Before scanning on the first session, partici-
pants were trained on the task to reduce practice effects that are common
in pharmacological designs with repeated testing. If the gap between
sessions was long, i.e., more than 1 week, participants were retrained on
subsequent sessions to refamiliarize them with the task.
Unblindingwas performed after the analysis of behavioral data and the
first-level analysis of fMRI data.
Probabilistic reversal task.The task used herewas similar to that used by
Cools et al. (2002). In each experimental session, each subject was
scanned while performing the behavioral task in three successive echo
planar imaging (EPI) runs, each lasting 8.5 min. Before entering the
scanner on the first day, subjects performed a 30 trial training session.
This was a simple probabilistic discrimination task (i.e., without reversal
stages) designed to introduce the subject to the concept of a probabilistic
error without the need to reverse responding (Fig. 1).
In the main task, on each trial the same two patterns were presented.
One of the patterns was correct and the other pattern was incorrect, and
subjects had to choose the correct pattern on each trial. During the task,
the rule changed intermittently so that the other pattern was correct. On
each block, the rule changed after a total of between 10 and 15 correct
responses (pseudorandomly varied from block to block). Subjects were
instructed to start choosing the other pattern only when they were sure
that the rule had changed. To prevent subjects from adopting a strategy
such as always reversing after two consecutive errors, probabilistic neg-
ative feedback was given on two consecutive trials once during each task
block.
The task was programmed in Microsoft Visual Basic 6.0, and stimuli
were presented on a computer display projected onto amirror in theMRI
scanner. Responses were made using the left or right button on a button
box positioned on the stomach of the subject. Different stimuli were used
in each of the three task blocks (and training stage), and the order of
presentation of the blocks was counterbalanced across subjects. Each
block consisted of 10 discrimination stages and, therefore, nine reversal
stages. Reversal of the stimulus–reward contingency occurred after be-
tween 10 and 15 correct responses (including probabilistic errors). The
two stimuli in each blockwere abstract colored patterns presented simul-
taneously in the left and right visual fields (location randomized). Dif-
ferent pairs of stimuli were used in each block of the task, with order
randomized across subjects. Responses were made using the left or right
button on a button box positioned on the stomach of the subject.
On each individual trial, the stimuli were presented for 2000mswithin
which the response had to be made (or else a “too late” message was
presented). Feedback, consisting of a green smiley face for correct re-
sponses or a red sad face for incorrect responses, was presented immedi-
ately after the response. The feedback faces were presented centrally,
between the two stimuli, for 500 ms during which the stimuli also re-
Figure 1. The probabilistic reversal-learning task. On each trial, subjects are presented with two abstract visual patterns.
Using trial-and-error feedback, subjects must discover which of the two patterns is correct (the subject’s choice is indicated here
with a small, black arrowhead). Feedback (a green smiley face or red sad face) is presented as soon as the subject has chosen one
of the patterns with a left or right button press.
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mained on the screen. After feedback, the stimuli were removed and the
face was replaced by a fixation cross for a variable interval so that the
overall interstimulus interval was 3253 ms.
Checkerboard task. Subjects viewed an 8 8 black and white checker-
board pattern that flashed at a frequency of 8 Hz. The visual presentation
alternated between 20 s of flashing checkerboard and 20 s of blank white
screen for a total of 4 min (six blocks of checkerboard and six blocks of
rest), allowing a block-related contrast of visual activity crosshair fix-
ation. There was no response requirement.
fMRI data acquisition and analyses. Participants were scanned at the
Wolfson Brain Imaging Centre (University of Cambridge, Cambridge,
UK) on a 3 T Bruker scanner using a head coil. Functional images were
collected using 21 slices covering the whole brain (slice thickness, 4 mm;
interslice gap, 1 mm; in-plane resolution, 1.56 1.56 mm) with an EPI
sequence (repetition time, 1.6 s; echo time, 27 ms; matrix size, 128 
128). The number of volumes acquired per run varied for each run from
320 to 380 because the number of correct responses before a rule
change varied pseudorandomly between 10 and 15 from block to block.
The first 12 volumes were discarded to allow for T1-equilibrium effects.
Structural and functional images were collected in the axial oblique
plane.
All fMRI data were preprocessed (transformed) using SPM2 (statisti-
cal parametric mapping software) and analyzed using SPM5 software
(Wellcome Department of Cognitive Neurology, London, UK). During
preprocessing before analysis, all images were corrected for slice timing,
subject motion corrected, and geometrically undistorted using phase
maps (Cusack et al., 2003). Using the mean realigned image, all images
were coregistered to a skull-stripped [using the Brain Extraction Tool
(Smith, 2002)] high-resolution structural scan (voxel size, 1  1  1
mm) that was acquired on the first scanning day. Images were then
normalized, using affine and smoothly nonlinear transformations, to an
EPI template inMontreal Neurological Institute (MNI) space. Finally, all
normalized images were spatially smoothed with a 10 mm full-width,
half-maximum Gaussian kernel.
The time series were high-pass filtered (128 s), and a canonical hemo-
dynamic response function was modeled to the onset of the responses,
which occurred at the same time as the presentation of the feedback. The
following events were modeled: (1) correct responses; (2) final reversal
errors (negative feedback followed by a response shift); (3) probabilistic
errors (on which erroneous negative feedback was given and the subject
did not shift their response); and (4) perseverative errors (errors gener-
ated by a change in contingency but onwhich the participant did not shift
their response). For the purposes of the analysis, probabilistic and perse-
verative errors were collapsed and are referred to as nonswitch errors: on
both types of errors, participants received negative feedback but did not
switch their response. In each testing session, the average number of trials
for each condition (across the three runs of the task) were as follows: final
reversal errors, 27; perseverative errors, 29; probabilistic errors, 45; cor-
rect responses, 374.
To delineate the general network of areas involved in performance of
the task independent of any drug effects, we computed a contrast, final
reversal errors  correct responses, at the subject-specific level only on
scans from the placebo condition. The contrast images from this com-
parison were taken to a second-level analysis involving a one-sample t
test to test for effects at the group level.
The preceding contrast is useful to reveal areas generally involved in
task performance. However, our central predictions were that dopami-
nergic drugs would modulate BOLD signal in different areas of this task
network during different cognitive subprocesses, specifically, that meth-
ylphenidate would modulate striatal BOLD signal during switching and
prefrontal BOLD signal during maintenance of the current response
“set.” Accordingly, we tested these hypotheses by examining the interac-
tion of the drugs with two more restricted contrasts designed to reveal
BOLD signal specifically related to the subprocesses of interest.
The first of these contrasts, final reversal errors  nonswitch errors,
investigated areas that were modulated by drug specifically during the
process of switching (subtracting out any activity related to receiving
negative feedback when there was no response switch). The second of
these contrasts, nonswitch errors correct responses, investigated areas
that were modulated by drug specifically during receipt of negative feed-
back when there was no response switch, i.e., when participants main-
tained the current mode of responding in the face of misleading negative
feedback.
We examined the drug effects by performing these two critical con-
trasts at the subject-specific level and taking the contrast images from
these comparisons to second-level group analyses involving separate 2
2 repeated-measures ANOVAs, with the factors methylphenidate (on vs
off) and sulpiride (on vs off). This enabled an examination of both the
main effects of drugs on process-specific activity and of the interaction
between the two drugs in their effects on this activity.
For all comparisons, the threshold set for statistical significance was
p  0.05, corrected for false discovery rate (FDR). All analyses were
performed on the whole-brain group data.
Results
Behavioral data
Two separate 2 2 repeated-measures ANOVAswere performed
on the behavioral data, with methylphenidate (on or off) and
sulpiride (on or off) as the two factors. The two ANOVAs exam-
ined the effects of these factors on two dependent measures: (1)
number of consecutive errors preceding a switch (perseverative
errors), and (2) probability of switching after erroneous feedback
[the number of probabilistic errors on which participants
switched response divided by the total number of probabilistic
errors (prob switch)]. There was no main effect of methylpheni-
date (perseverative errors, F(1,16)  0.36, p  0.55; prob switch,
F(1,16) 0.26, p 0.62), nomain effect of sulpiride (perseverative
errors, F(1,16)  0.12, p  0.73; prob switch, F(1,16)  0.24, p 
0.63), and no methylphenidate  sulpiride interaction (perse-
verative errors, F(1,16) 1.48, p 0.24; prob switch, F(1,16) 2.4,
p 0.14) .
fMRI data
Task-related activity
To investigate task-related activations, an initial contrast was per-
formed at the random-effects level, only including scans from the
placebo session. This contrast, final reversal errors correct re-
sponses, revealed an extensive network of activated areas (Fig. 2,
Figure 2. Whole-brain SPM showing the results of the contrast final reversal errors correct
responsesperformedat the random-effects level on scans fromtheplacebo condition, superimposed
on the MNI template brain. Results are corrected for FDR ( p  0.05). Color scale represents
magnitude of t values.
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Table 1). This included a large cluster extending from the anterior
cingulate cortex (ACC), into ventrolateral prefrontal cortex
(VLPFC), striatum (including the putamen), and thalamus.
Drug effects on process-specific BOLD responses
The first of the contrasts examining drug effects on process-
specific BOLD response was performed on the contrast images
from the comparison final reversal errors  nonswitch errors.
This revealed a highly selective, significant effect of methylpheni-
date bilaterally in the ventral putamen (Fig. 3), as well as smaller
peaks in the right precentral gyrus and right cuneus. The activa-
tion in the right putamen remained significant even at the more
conservative familywise error rate (FWE) threshold of p 0.05.
As shown in Figure 4 and supplemental Figure 1 (available at
www.jneurosci.org as supplemental material), this region showed a
reduced BOLD response on reversal trials in the methylphenidate
and combined drug conditions relative to the sulpiride and placebo
conditions. No areas showed significant modulation by sulpiride,
and no areas showed a significant methylphenidate  sulpiride
interaction.
To confirm that there was no drug effect on BOLD signal in
the PFC during switching, the statistical threshold was dropped
to the more liberal p 0.001 uncorrected for multiple compari-
sons. Even at this more liberal threshold, there was no significant
drug effect on BOLD signal in any prefrontal or parietal cortical
regions.
The second of these contrasts, performed on the contrast images
from the comparison nonswitch errors  correct responses, re-
vealed significant effects of methylphenidate in bilateral VLPFC,
ACC, rightdorsolateral prefrontal cortex, rightprecentral gyrus, and
bilateral inferior parietal lobe (Fig. 5). As shown in Figure 6 and
supplemental Figure 2 (available at www.jneurosci.org as supple-
mental material), these effects in VLPFC and ACC are actually
driven by an attenuation of deactivation during correct responses in
themethylphenidate condition relative to the placebo condition or,
in other words, a methylphenidate-induced increase in BOLD re-
sponseduring correct responses.Therewasnoeffect of sulpiride and
no interaction between methylphenidate and sulpiride in this
contrast.
Finally, despite the absence of a significant interaction be-
tween methylphenidate and sulpiride, our previous hypothesis
that sulpiride would reverse the effects of methylphenidate justi-
fied performing simple effects analyses to see whether activity in
the combined condition was significantly different from activity
in themethylphenidate condition. Student’s t tests performed on
both of the contrasts described above comparing the methyl-
phenidate and combined conditions revealed no regions inwhich
activity varied significantly between these two conditions.
Checkerboard task
Analysis of the fMRI data from the passive viewing task revealed,
as expected, a widespread increase in activation in visual cortex
during visual stimulation relative to the rest condition. The peak
of the most highly activated cluster was at coordinates (10,96,
4), with an F value of 375, significant at p 0.05 corrected for
Table 1. Areas of activation from the whole-brain contrast final reversal errors
correct responses in the placebo condition
Talairach coordinates
Anatomical location x y z t value
Medial frontal gyrus 2 26 40 10.7
Inferior frontal gyrus 38 22 4 9.25
Insula 30 22 0 9.21
Middle frontal gyrus 38 12 52 8.82
46 28 26 8.51
Precuneus 32 64 42 8.56
Superior frontal gyrus 26 58 8 8.01
Inferior parietal lobule 32 54 46 7.98
Thalamus 14 12 6 7.75
To provide precise coordinates of activated clusters, only clusters that survive correction for FWE (p 0.05) and
contain at least 20 voxels are reported.
Figure 3. Whole-brain SPM showing areas in which there was a significant interaction be-
tween methylphenidate and condition in the random-effects contrast final reversal errors
nonswitch errors, superimposed on theMNI template brain. Methylphenidate reduced switch-
related activity bilaterally in the ventral putamen,with small peaks also in the right cuneus and
right precentral gyrus. In this figure, higher-intensity values represent a greater
methylphenidate-induced decrease in BOLD response. The figure displays all significantly acti-
vated clusters below a threshold of p 0.05, FDR corrected, containing at least 20 voxels. Color
scale represents magnitude of F values. The right putamen was also activated at the more
conservative threshold of p 0.05, FWE corrected.
Figure 4. Mean parameter estimates for final reversal errors and nonswitch errors in the
right putamen. For each subject, beta values were extracted from a region of interest (ROI)
based on the activated cluster from the second-level contrast, which showed a main effect of
methylphenidate on BOLD signal in the contrast final reversal errors nonswitch errors. This
region is shown in Figure 3. Beta values were then averaged across the three task sessions and
across all subjects to obtain a mean beta value for each event in each drug condition. These
values were then averaged across the methylphenidate and combined drug conditions and
across the sulpiride andplacebodrug conditions to show themain effect ofmethylphenidate on
switch-related BOLD signal. ROI definition and beta value extraction were performed with the
ROI toolbox Marsbar (Brett et al., 2002). Error bars represent SEM.
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FDR. The remaining activated clusters were all in a similar region
of visual cortex. Comparison of the activationmaps from the four
different drug conditions revealed no effects of methylphenidate
or sulpiride on brain activity. To confirm the absence of a drug
effect, the threshold for statistical significance was dropped to a
more liberal 0.001 uncorrected formultiple comparisons. Even at
this liberal threshold, there were no significant drug effects in any
voxel.
Discussion
We found that the precise neural site of modulation by methyl-
phenidate depends on the cognitive process being performed;
methylphenidatemodulated BOLD signal in the putamen during
response switching butmodulated BOLD signal in the PFCwhen
subjects maintained their current response set. There was no ef-
fect of methylphenidate on switch-related BOLD signal in any
prefrontal cortical regions, and there was no effect of methyl-
phenidate on BOLD response during nonswitch trials in the pu-
tamen. This is the first study to show thatmethylphenidate exerts
differential effects at cortical and striatal sites to affect distinct
cognitive components within a single task, in an event-related
fMRI paradigm.
The modulation of BOLD signal in the putamen during
switching may be related to the cognitive inhibitory component
of the task. When the stimulus–reward contingencies change,
participants must inhibit responding to the previously rewarded
stimulus and shift their response to the previously incorrect stim-
ulus. Thus, themodulation of putamen activity cannot be related
to a simple inhibition of a prepotent motor response, as in the
important study by Vaidya et al. (1998). Effects on motor inhibi-
tion per se are precluded by an important feature of the probabi-
listic reversal learning task, that the location of each stimulus, and
consequently the stimulus–response mapping, is randomized on
each trial such that participants do not know in advance of stim-
ulus presentation which button is associated with the presently
correct stimulus. Thus, the present finding shows that methyl-
phenidate modulates striatal activity not only during simple mo-
tor inhibition but also during inhibition of more abstract stimu-
lus–reward associations.
These data indicate a putativemechanism of stimulant action,
which could in principle be mediated by either dopamine or
noradrenaline (Gatley et al., 1996; Spencer et al., 1996; Kuczenski
and Segal, 1997). However, the relative paucity of noradrenaline
compared with dopamine in the striatum makes noradrenergic
mediation an unlikely explanation (Herregodts et al., 1991). Fur-
thermore, positron emission tomography (PET) imaging data
show that methylphenidate is very effective in blocking dopa-
mine transporters (Volkow et al., 1998), and studies involving
patients with Parkinson’s disease provide support for the impor-
tant role for striatal dopamine in behavioral flexibility (Cools et
al., 2001, 2007).
Thus, assuming that any effect of methylphenidate on norad-
renergic function within the striatum would be minimal, the
present data support and extend previous findings that dopami-
nergic signaling in the striatum plays an important role in exec-
utive control. Dopamine neurons in the striatum encode reward
prediction errors, facilitating learning by providing information
about the difference between obtained and expected rewards
(Schultz et al., 1997). The present data suggest that dopaminergic
modulation of neural activity in the putamen is especially impor-
tant when subjects change their behavior on the basis of negative
feedback. These findings support a model of executive control in
which dopaminergic signals originating in the striatum facilitate
the flexible updating of new goal-related representations (Frank
et al., 2001; Cools et al., 2007b).
In the absence of any behavioral effect of the drug, the reduc-
tion in BOLD signal in the striatummay reflect an increase in the
efficiency of executive control. This interpretation is consistent
with previous findings that amphetamine increases the efficiency
of prefrontal working memory processing in lower performing
subjects (Mattay et al., 2003) and also with the results of a previ-
ous PET study showing that methylphenidate-related improve-
ments in spatial workingmemory are associatedwith task-related
reductions in regional cerebral blood flow in the dorsolateral
prefrontal cortex (Mehta et al., 2000). However, an alternative
explanation is that the relatively high dose of methylphenidate
used in the present study placed our participants on the right side
of an inverted U-shaped dose–response function relating dopa-
mine levels to behavioral performance. This is consistent with the
results of the Vaidya et al. (1998) study, which revealed that
methylphenidate reduced striatal BOLD signal in healthy con-
trols but increased BOLD signal in ADHD patients, suggesting
that the precise effects of methylphenidate may depend on base-
line catecholamine levels.
The absence of any effect of the D2/D3 receptor antagonist
sulpiride on brain activity or behavior makes it difficult to make
any definitive conclusion about the role of specific dopamine
receptors in these effects. However, it is likely that too small a
dose of sulpiride was used, resulting in the absence of any observ-
able effect on brain activity. Although previous studies that used
a 400 mg dose found subtle effects of neurocognitive testing
(Mehta et al., 1999), a recent PET study by Mehta et al. (2007)
found that a single 400 mg dose of sulpiride (the same dose as
used in the present study because of ethical constraints in testing
higher doses) leads to only 28% occupancy of dopamine D2 re-
ceptors in the striatum. In contrast, 60 mg of methylphenidate
Figure 5. Whole-brain SPM showing areas in which there was a significant interaction be-
tween methylphenidate and condition in the random-effects contrast nonswitch errors 
correct responses, superimposed on theMNI template brain. Therewas a significant interaction
in several different areas. Prominent peaks were observed in ACC and bilateral VLPFC. In this
figure, higher-intensity values represent a greater methylphenidate-induced decrease in BOLD
response. However, as Figure 6 shows, this effect is driven by a methylphenidate-induced
increase in activation for correct responses. Color scale represents magnitude of F values. The
figure displays all significantly activated clusters below a threshold of p 0.05, corrected for
false discovery rate, containing at least 20 voxels.
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(the same dose as used in the present study) has been shown to
lead to a much higher percentage occupancy (74%) of the dopa-
mine transporter (Volkow et al., 1998). Thus, 400mg of sulpiride
may not have been a sufficiently large dose to cause observable
changes in BOLD signal in the striatum.
The results of the task-specific analysis replicated the findings
of Cools et al. (2002), who, using exactly the same task, found an
increase in activation in the VLPFC for final reversal errors rela-
tive to correct responses. However, despite the widespread in-
creases in PFC activity associated with reversals when examined
independently of any drug effects, we did not observe any mod-
ulation of PFC activity by methylphenidate during response
switching. In fact, methylphenidate modulated activity in the
ACC and lateral PFC during receipt of correct feedback that was
not followed by a subsequent response switch.
Given thewidespread distribution of both dopamine and nor-
adrenaline projections to the PFC, we cannot rule out the possi-
bility that the observed drug effects in the PFC reflectmodulation
of noradrenergic signaling. Indeed, therapeutic doses of methyl-
phenidate with cognitive enhancing effects increase the efflux of
both dopamine and noradrenaline in the rat PFC (Berridge et al.,
2006).However, the presentmodulation of PFC activity bymeth-
ylphenidate appears to be consistent with the hypothesized role
of dopamine D1 receptors in stabilizing goal representations in
the face of distracting information (Durstewitz and Seamans,
2002).
The effects of methylphenidate observed in the present study
contrastwith the effects of tryptophandepletion (whichnormally
reduces central 5-HT levels) on BOLD signal during reversal
learning observed by Evers et al. (2005). In that study, tryptophan
depletion increased BOLD signal during negative feedback in a
region of medial PFC, which was more dorsal than the ACC
region modulated by methylphenidate in the present study.
There was also no modulation in the study by Evers et al. (2005)
of BOLD signal in VLPFC during performance monitoring or
striatal BOLD signal during switching. The differential neural
effects of tryptophan depletion andmethylphenidate during per-
formancemonitoringmay reflect different functional roles of the
indoleamine serotonin and the catecholamines, respectively,
during reversal learning. Indeed, tryptophan depletion modu-
lated medial PFC activity during negative feedback, whereas
methylphenidate modulated activity in a nearby medial PFC re-
gion during positive feedback. This suggests that serotonin and
the catecholamines may play complementary roles in reversal
learning, with serotoninergic modulation of PFC activity medi-
ating the processing of aversive signals and
catecholaminergic modulation of PFC ac-
tivity mediating the processing of positive
signals (cf. Clarke et al., 2007).
Interestingly, the putaminal region in
which methylphenidate modulated BOLD
signal in the present study is different from
the ventral striatal region in which levo-
dopa modulated BOLD signal in patients
with Parkinson’s disease during reversal
learning (Cools et al., 2007b). One possible
reason for this discrepancy is that the study
by Cools et al. (2007b) involved patients
with presumably abnormal dorsal striatal
dopamine levels. It is likely that any effects
of dopaminergic drugs on dorsal striatal
BOLD signal in healthy volunteers will be
abnormal in such patients.
In summary, we observed different effects ofmethylphenidate
on cortical and subcortical BOLD signal related to distinct behav-
ioral processes. Methylphenidate reduced activity in the ventral
putamen during switching after negative feedback and increased
activity in the PFC during maintenance of the current response
set. These data suggest that the precise neural effects of methyl-
phenidate during the performance of a cognitive task will depend
on the extent to which that task recruits the separate neural sys-
tems involved in the stabilization and flexible updating of goal-
related representations.
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